Erin Wilkinson, APRN
Family · Las Vegas, NVNPI 1497383020
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Novartis at 29.4% of the total. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $280.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$13K
- EMD Serono, Inc.$7K
- Sanofi$7K
- Amgen$7K
- TG Therapeutics, Inc.$5K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $2K from 5 others
What the payments were for
- Consulting fees$22,62652%
- Speaking & faculty fees$5,00312%
- Travel & lodging$6,53815%
- Food & beverage$8,96721%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $12,705 |
| EMD Serono, Inc. | 31 | $7,407 |
| Sanofi | 18 | $7,305 |
| Amgen(2 entities) | 28 | $6,711 |
| TG Therapeutics, Inc. | 27 | $5,073 |
| E.r. Squibb & Sons, L.L.C. | 5 | $1,654 |
| Bristol Myers Squibb | 8 | $1,238 |
| Biogen | 3 | $396 |
| Cycle Pharmaceuticals Inc | 1 | $383 |
| Banner Life Sciences, LLC | 1 | $332 |
| AstraZeneca | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,234 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 20 | $802,564 |
| Kesimpta PenOfatumumab | 57 | $525,741 |
| AubagioTeriflunomide | 19 | $194,894 |
| CopaxoneGlatiramer Acetate | 27 | $194,129 |
| TecfideraDimethyl Fumarate | 20 | $186,552 |
| RebifInterferon Beta-1a/Albumin | 13 | $133,975 |
| MayzentSiponimod | 11 | $122,642 |
| VumerityDiroximel Fumarate | 12 | $115,103 |
| BetaseronInterferon Beta-1b | 12 | $114,152 |
| AmpyraDalfampridine | 16 | $111,425 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 11 | $102,787 |
| FingolimodFingolimod Hcl | 27 | $102,163 |
| Dimethyl Fumarate | 24 | $45,071 |
| Dalfampridine ErDalfampridine | 119 | $42,322 |
| GlatopaGlatiramer Acetate | 12 | $27,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Vumerity | $396 | $301,65532 claims |
| SanofiAubagio | $7,305 | $194,89419 claims |
| EMD Serono, Inc.Rebif | $7,407 | $133,97513 claims |
| NovartisMayzent | $12,705 | $122,64211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Kelly PapeshLas Vegas$28K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
- Anuradha ThirumalaiLas Vegas$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.